Advertisement
Advertisement

RVPH

RVPH logo

Reviva Pharmaceuticals Holdings, Inc. Common Stock

0.29
USD
Sponsored
+0.03
+12.55%
Feb 06, 15:58 UTC -5
Closed
exchange

After-Market

0.30

+0.01
+3.83%

RVPH Earnings Reports

Positive Surprise Ratio

RVPH beat 13 of 18 last estimates.

72%

Next Report

Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.07
Implied change from Q3 25 (Revenue/ EPS)
--
/
+16.67%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-53.33%

Reviva Pharmaceuticals Holdings, Inc. Common Stock earnings per share and revenue

On Nov 13, 2025, RVPH reported earnings of -0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 39.46% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an increase of 16.67% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
For Q3 2025, Reviva Pharmaceuticals Holdings, Inc. Common Stock reported EPS of -$0.06, beating estimates by 39.46%, and revenue of $0.00, 0% as expectations.
The stock price moved down -7.19%, changed from $0.54 before the earnings release to $0.50 the day after.
The next earning report is scheduled for Mar 30, 2026.
Based on 10 analysts, Reviva Pharmaceuticals Holdings, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement